ArticleEuropean journal of neurology2026
Reduced Frequency of Prolonged Sporadic Hemiplegic Migraine Attacks Following Fremanezumab Treatment-A Case Report.
Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reduced Frequency of Prolonged Sporadic Hemiplegic Migraine Attacks Following Fremanezumab Treatment-A Case Report.European journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHemiplegic migraine (HM) is a rare subtype of migraine with aura, characterized by transient, unilateral motor weakness. Due to its rarity, treatment strategies are lacking. Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway have emerged as a potential therapeutic option. CASE REPORT: A 64-year-old man was admitted to an Austrian stroke unit with acute aphasia, right-sided hemiplegia, and reduced consciousness. MRI showed no ischemia or hemorrhage. Cerebrospinal fluid analysis revealed pleocytosis (146 cells/μL) without signs of infection. By Day 4, the patient showed improving hemiparesis and new-onset hemicranial headache. Aphasia resolved by Day 14 and hemiparesis by Day 21. The patient's history included non-Hodgkin lymphoma with cerebral relapse, treated with whole-brain irradiation and stem cell transplantation in 2007, and a history of migraine with aura. Differential diagnoses such as SMART syndrome and HaNDL were considered, but the improvement of symptoms following headache onset and the prior migraine history supported the diagnosis of sporadic hemiplegic migraine (SHM). Genetic testing revealed no mutations associated with familial HM. Initial treatment with lamotrigine was followed by monthly fremanezumab (225 mg). No further HM attacks occurred over 6 months of follow-up.
conclusionThis case illustrates the diagnostic complexity of SHM and adds to the growing body of anecdotal observations suggesting that CGRP monoclonal antibodies may be a promising preventive treatment for patients with HM. Further studies are needed to evaluate their efficacy in this rare migraine subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.